Supervisory board

• Prof. Mark de Boer
• Oscar Schoots
• Christina Takke
• Michel Briejer
• Edward van Wezel

Prof. Mark de Boer (1960), PhD,

who for the last fifteen years has worked for, managed and started early stage biopharmaceutical companies in the field of innovative novel biopharmaceuticals. He most recently served as CEO of 4AZA Bioscience, a small Belgium Biotech start-up company, before that, he was until 2003 CEO of MacroZyme B.V. and until 2001 Managing Director of Tanox Pharma B.V. Dr. de Boer serves as a member of the supervisory board of several Biotech companies, and is venture partner for Index ventures. He is also a professor on the faculty of pharmaceutical sciences of the University of Utrecht (The Netherlands) in the field of entrepreneurship in life sciences.

Oscar Schoots (1966), PhD,

has been working for "University Utrecht Holding BV" and "UMC Utrecht Participations" as of 2002. His responsibilities include the patent portfolio and technology transfer activities from the Utrecht University (UU) and Medical Center (UMC). In addition, he has been involved in the incorporation of several spin off companies. From 1993 to 1996 he conducted research at the University of Toronto (Canada) and received a Ph.D. in medicine from UU. Following two years postdoctoral research at the Rudolf Magnus Institute in Utrecht (1997-1998), Dr. Schoots started working for Licentec, a specialized independent technology transfer organization (1999-2002). He worked for universities, hospitals and their spin offs, venture capitalists and industry. In 2001-2002 he was actively involved in the incorporation of a small medical device company in Amsterdam and served as managing director. On behalf of the shareholders of Seed Capital Investments, he reorganized this small seed capital investment fund in 2001-2002. In order to broaden his experience, Dr. Schoots obtained his MBA in 2002 (Bradford University/NIMBAS)

Christina Takke (1970), PhD,

has been working as a Principle at Forbion Capital Partners since 2007. She holds degrees from University of Cologne and Technische Universität Darmstadt. At Forbion Dr. Takke is responsible for scouting of new investment opportunities as well as for their scientific/ technical analysis and monitoring. In 2000 she joined ABN AMRO and was part of the Life Sciences group until 2006. Prior to ABN AMRO, Dr. Takke worked at Bio-Gen-Tec-NRW, a regional development organization for biotechnology based in Cologne, Germany. Here she evaluated business proposals and assisted companies in the fundraising process. Dr. Takke serves on the supervisory board of Pieris AG (Germany), and was an observer on the board of GlycArt (Switzerland) prior to its sale to Roche in 2005.

Michel Briejer (1965), PhD,

is an Investment Director at Thuja Capital. Prior to joining Thuja Capital, Michel held senior R&D management positions at Janssen Pharmaceutica (Belgium), Yamanouchi Europe (currently Astellas Pharma) and Crucell. Moreover, he worked as a consultant for a number of small pharmaceutical and biotech start-up companies in The Netherlands. As a former project leader in charge of various drug development programs, he understands the complexity of drug development and project management, irrespective of whether it concerns chemically synthezised compounds or biotechnology-derived drugs, bringing 17 years of strategic and operational drug development know-how. Michel holds a Master of Science degree in Pharmacy (Utrecht University) and a PhD in Pharmacology (Wageningen University), as well as a post-doctoral degree in Pharmaceutical Medicine (European Center for Pharmaceutical Sciences, Basle). Michel authored over 25 peer reviewed scientific papers and book chapters on pharmacology and drug development.

Edward van Wezel (1964), M.Sc.,

has been working as Managing Partner at BioGeneration Ventures since 2006. Edward holds a M.Sc in biochemistry from the University of Utrecht and a M.Sc in Biochemical Engineering from the University of Delft. At BioGeneration Ventures Edward holds overall responsibility and is actively involved in evaluation of new business plans and assists portfolio companies in business development. Prior to BioGeneration Ventures Edward was director business development and managing director at several start-up and early stage life sciences companies in the Netherlands and gained industrial experience at Johnson & Johnson and Chiron. Mr Van Wezel serves on the supervisory board of Progentix B.V. and NovioGendix B.V..